Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Oak Crest Institute Of Science has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners, which provides diversity in the examination process. However, both matters are situated within a distinct art unit, indicating that the technical focus remains within a single specialized group at the patent office. This structure allows the institute to receive multiple perspectives on its technical disclosures.
JAUHARI, SACHI is the busiest examiner for the institute, holding 1 pending office action. This represents a portion of the workload when viewed alongside the other active case. The use of multiple examiners within the Biotechnology & Pharmaceuticals sector suggests that while the technical field is narrow, the institute is interacting with different individuals. This distribution of active matters allows for varied examiner perspectives, even as JAUHARI, SACHI manages only the 1 pending office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WRIGHT, SARAH C | 1 | 41.6% | +46.0% |
| JAUHARI, SACHI | 1 | 60.0% | +80.0% |
| BEANE, RANDALL L | 1 | 32.8% | +36.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18017582 | MATERIALS AND METHODS FOR THE PREVENTION AND TREATMENT OF VIRAL RESPIRATORY DISEASES | BEANE, RANDALL L | 70d |
| 18725371 | Subdermal Implant for Sustained Drug Delivery | WRIGHT, SARAH C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18017582 | MATERIALS AND METHODS FOR THE PREVENTION AND TREATMENT OF VIRAL RESPIRATORY DISEASES | BEANE, RANDALL L | 70d |
| 18725371 | Subdermal Implant for Sustained Drug Delivery | WRIGHT, SARAH C | — |
| 18287202 | MATERIALS AND METHODS FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES | JAUHARI, SACHI | — |
| Art Unit | Apps |
|---|---|
| 1654 | 2 |
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18725371 | Subdermal Implant for Sustained Drug Delivery | WRIGHT, SARAH C | 1619 | §102§103§112Other | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18287202 | MATERIALS AND METHODS FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES | JAUHARI, SACHI | 1654 | §112Other | Non-Final OA | — | Pending | Oct 17, 2023 |
| 18017582 | MATERIALS AND METHODS FOR THE PREVENTION AND TREATMENT OF VIRAL RESPIRATORY DISEASES | BEANE, RANDALL L | 1654 | §103§112 | Final Rejection | 70d | Pending | Jan 23, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial